Mednet Logo

In patients with cholangiocarcinoma who qualify for HAIP therapy, would you recommend treating with chemotherapy and immunotherapy?

PUMP-2 trial combined FUDR via HAIP with gemcitabine and cisplatin, no immunotherapy was on the protocol.
3 Answers
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Rutgers Cancer Institute of New Jersey
Answered on

While HAIP is considered promising (again - 20 years later), no appropriate phase III trial has shown benefit in any diagnosis. Since phase III trials support immunotherapy, that is preferred.

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Medical Oncology · NYU Grossman School of Medicine
Answered on

Thank you for the question. I agree that the HAIP can be an effective option for carefully selected patients ineligible for resection in the hands of experts experienced with HAIP- and has offered improvements in PFS & OS. However, to date, published data has only been in combination with cytotoxic ...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty
Answered on · Updated on

Based on the concept that hepatic metastases derive most of their blood supply from the hepatic artery as opposed to venous system hepatic arterial infusion (HAI) has been evaluated in the past for mostly colorectal cancer patients with hepatic metastases. (Copur et al., PMID 11331319, Kemeny et al....

Join for free or sign in to see the full answer